Putting adoptive T cell therapy on the path to regulatory approval
Putting adoptive T cell therapy on the path to regulatory approval
Using Hsp90 inhibitors in the clinic: what have we learned?
Radiogenomic evaluation of tumour response to targeted agents
Mutant-specific kinase inhibitors and TAT highlights
New drugs and targets in haematological malignancies
Drugging the cancer genome to overcome drug resistance
VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma
Combination of pazopanib and paclitaxel safe in urothelial cancer
Tackling renal cancer with a combination of autologous immunotherapy and sunitinib
Challenging results from mTOR inhibitors in metastatic clear cell renal cancer
Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction
mRCC: Real-world experience: achieving efficacy beyond clinical trials